Top Page
Epsilon Healthcare Limited
(Sydney:EPN)
Epsilon Healthcare Limited (EPN) vs. iShares MSCI Australia ETF (EWA)
Epsilon Healthcare Limited Business Overview & Revenue Model
Epsilon Healthcare Limited Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.39M | 5.60M | 6.65M | 7.11M | 5.50M |
| Gross Profit | 2.25M | 4.17M | 4.81M | -3.09M | 2.06M |
| EBITDA | -1.86M | -2.13M | -1.31M | -10.86M | -8.09M |
| Net Income | -2.05M | -3.25M | -1.09M | -13.29M | -8.91M |
Balance Sheet | |||||
| Total Assets | 17.87M | 22.26M | 14.41M | 20.50M | 30.55M |
| Cash, Cash Equivalents and Short-Term Investments | 242.86K | 1.57M | 343.01K | 861.99K | 2.34M |
| Total Debt | 14.16M | 7.88M | 3.45M | 3.20M | 4.33M |
| Total Liabilities | 14.88M | 11.57M | 6.87M | 11.23M | 10.98M |
| Stockholders Equity | 2.99M | 10.70M | 7.54M | 9.27M | 19.57M |
Cash Flow | |||||
| Free Cash Flow | -3.30M | -3.50M | -803.47K | -3.10M | -6.18M |
| Operating Cash Flow | -3.13M | -3.41M | -703.37K | -2.57M | -5.43M |
| Investing Cash Flow | 6.29M | -97.73K | -99.12K | -529.40K | -737.59K |
| Financing Cash Flow | -4.48M | 4.73M | 335.91K | 1.61M | 1.47M |
Epsilon Healthcare Limited Technical Analysis
Epsilon Healthcare Limited Peers Comparison
Epsilon Healthcare Limited Corporate Events
Epsilon Healthcare Limited reported a 68% increase in revenue from ordinary activities to $9.39 million for the year ended 31 December 2025, reflecting strong top-line growth in its healthcare operations. The company did not declare any interim or final dividend for the period, indicating a continued focus on reinvesting cash to support its development and financial consolidation.
The loss from ordinary activities after tax attributable to members fell by 63% to $2.05 million, while net profit attributable to members rose 129% to $2.96 million, highlighting a significant improvement in overall profitability. These results suggest enhanced operational efficiency and a strengthening financial position, which may improve Epsilon Healthcare’s standing with investors and support its competitiveness in the healthcare market.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has applied for quotation on the ASX of 5,000,000 new ordinary fully paid shares under the ticker EPN, with an issue date of 10 February 2026. The additional securities, arising from the exercise or conversion of existing instruments, will expand the company’s quoted share capital and may influence its liquidity and capital structure for investors.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has applied to the ASX for quotation of 5 million new fully paid ordinary shares, issued on 4 February 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s share base and potentially providing incremental capital or aligning holders of the converted instruments more closely with ordinary shareholders.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare’s Epsilon Pharma unit has signed a three-year commercial manufacturing agreement with Puro New Zealand, the country’s largest medicinal cannabis cultivator, to produce GMP-certified finished products for export initially to the UK and later to wider European markets. The deal, forecast to generate about A$6 million in revenue over the initial term and representing roughly 25% of Epsilon Pharma’s 2025 revenue base, strengthens Epsilon’s CDMO pipeline, showcases its EU GMP-compliant capabilities, and marks a significant step in its strategy to expand its international footprint, support Puro’s UK and European market entry, and deliver incremental, long-term revenue growth for shareholders starting from Q1 2026.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare’s wholly owned subsidiary Epsilon Pharma has secured Halal Australia certification for its CBD and THC oil dosage forms, confirming that its Australian manufacturing operations meet stringent Halal requirements and comply with the GSO/UAE.S 2055-1 standard for handling, processing, storage and distribution. The accreditation is positioned as a key endorsement of the company’s advanced, compliant manufacturing capabilities and is expected to open access to Halal-regulated markets in the Middle East, Southeast Asia and other regions, supporting new international partnerships, expansion into Halal-compliant markets and long-term strategic growth in premium regulated product segments.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare reported record quarterly customer receipts of $2.891 million for the December 2025 quarter, a 96% increase on the prior corresponding period, and full-year receipts of $9.175 million, up 71% year-on-year, highlighting a strong turnaround with group revenue now exceeding $1 million per month. The company’s reinstatement to trading on the ASX in December capped a period of operational recovery driven by growth across its CDMO arm, clinics and newly launched pharmacy, supported by an R&D tax incentive and expanding domestic and international client base, positioning Epsilon for scalable growth and a clearer path toward sustainable profitability.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has disclosed a change in director Zoe Hutchings’ shareholding, reflecting her direct ownership of fully paid ordinary shares in the company. The filing indicates a routine on‑market purchase rather than any alteration to contractual interests or trades during a closed period.
Hutchings acquired 307,934 shares on 8 January 2026 for approximately $10,856.78, increasing her holding from 1,761,192 to 2,069,126 shares. The transaction, conducted as an on‑market purchase and outside any closed period, signals increased personal exposure by the director without any associated changes in derivative positions or other security-related contracts.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has disclosed a change in director Zoe Hutchings’ shareholding, indicating an increase in her direct ownership of the company’s fully paid ordinary shares. The filing shows that Hutchings acquired 519,426 shares through an on‑market purchase over 29–30 December 2025, lifting her total holding to 1,761,192 shares, a move that may be interpreted by investors as a signal of confidence in the company’s outlook and governance stability.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has disclosed a change in director Zoe Hutchings’ holdings, reflecting an increase in her personal share investment in the company. On 19 December 2025, Hutchings purchased 40,000 fully paid ordinary shares on‑market for approximately $1,005, lifting her direct holding to 1,241,766 shares, with the trade conducted during a closed period under prior written clearance, signalling continued insider confidence without any associated contractual changes.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has confirmed that all resolutions put to shareholders at its latest Annual General Meeting were passed by poll, signaling solid shareholder backing for the company’s current strategy and governance. The board highlighted the outcome as a vote of confidence from investors, which may support continuity in its diversified healthcare, pharmaceutical manufacturing, and pharmacy services operations as it pursues its broader growth objectives.
The most recent analyst rating on (AU:EPN) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has had its securities reinstated to quotation on the ASX following a suspension and its emergence from voluntary administration in June 2024, after satisfying the exchange’s conditions. The company has undertaken an extensive internal overhaul of its operations, financial position, governance and disclosure practices, which the board and management say has stabilised the business, rebuilt stakeholder confidence and positioned Epsilon to pursue a disciplined and sustainable growth strategy. Over the next 12 months, Epsilon plans to scale its core capabilities in manufacturing, pharmacy and clinical services, develop new products and services, leverage its GMP infrastructure for scalable growth, expand its clinical and pharmacy offerings, and seek strategic opportunities to diversify revenue and strengthen operational resilience. The board also continues a professionally guided legal, forensic and financial review of historical matters involving former directors to ensure shareholder and company interests are protected and, where appropriate, remediated, underscoring a renewed emphasis on governance, transparency and long-term shareholder value.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has had its securities reinstated to trading on the ASX, with the exchange confirming that the company has met all required conditions for quotation to resume. The lifting of the trading suspension, effective from the start of trading on 19 December 2025, restores market liquidity for shareholders and signals regulatory confidence in the company’s compliance status.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has announced its progress towards the reinstatement of its securities on the Australian Securities Exchange following a suspension period. The company has conducted a thorough review of its operations, governance, and financial standing to ensure transparency and compliance, positioning itself for a sustainable growth strategy upon reinstatement. EPN confirms no material information is outstanding, aligning its operations with ASX regulations and maintaining readiness to meet future investor expectations.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited announced measures to reinforce its working capital position, including a $2,000,000 loan facility from its Managing Director, deferral of repayment deadlines for loans and fees owed to directors until 2027, and adjustment of obligations for management salaries and incentives. These actions, underscored by significant contributions from the leadership, reflect strong confidence in the company’s future prospects and enhance its financial stability to support ongoing operations and stakeholder interests.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited reported a 19% increase in revenue to $3.4 million for the half-year ending June 2025, driven by new client engagements and the successful launch of Epsilon Pharmacy. Despite the revenue growth, the company experienced a net loss of $2.07 million, attributed to administrative fees, interest, and loan charges, as well as costs associated with remediation work due to voluntary administration.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.
Epsilon Healthcare Limited has announced a change in its external auditor, appointing RSM Australia effective December 16, 2025. This decision is part of the company’s commitment to strong corporate governance and aligning its audit framework with operational needs and strategic growth objectives, following the resignation of A D Danieli Audit with ASIC’s consent.
The most recent analyst rating on (AU:EPN) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Epsilon Healthcare Limited stock, see the AU:EPN Stock Forecast page.